VSTM250117C1000
- 3.90
- 0.000.00%
Verastem Newsroom
Verastem Is Maintained at Outperform by RBC Capital
Verastem Price Target Raised to $16.00/Share From $13.00 by RBC Capital
Verastem Analyst Ratings
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $16
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
Momentum Reigned 2024: Buy-rated U.S. Stocks With the Highest RSI
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
Sector Update: Health Care Stocks Lower in Afternoon Trading
Sector Update: Health Care
US Equity Indexes Trend Lower in Midday Trading
Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?
Express News | Verastem Shares up 32% After FDA Grants Priority Review for Ovarian Cancer Combo Therapy
Traders Cautious as 2024 Draws to Close, Stifling US Equity Futures Pre-Bell
FDA To Decide On Verastem's Avutometinib & Defactinib For A Subtype Of Serous Ovarian Cancer In June
Top Premarket Gainers
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $20
BTIG Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $20
Verastem Price Target Raised to $20 From $13 at BTIG